Find Funding Opportunities

The National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), and National Institute of Allergy and Infectious Disease (NIAID) invite research grant applications to address the problem of HIV-1 persistence focused solely on the central nervous system (CNS) of HIV-infected persons treated with Highly Active Anti-Retroviral Therapy (HAART). This Funding Opportunity Announcement (FOA) will support innovative research in five areas: (1) basic research to identify and characterize CNS-based cellular reservoirs of HIV-1 for individuals on HAART; (2) basic research to determine the mechanisms involved in the temporal establishment, maintenance, and resurgence of CNS-based HIV-1 reservoirs in relationship to the effects and timing of HAART, viral expression, and viral evolution within the brain; (3) development of physiologically relevant animal models and CNS-based cellular assays that recapitulate HIV-1 persistence and latency in the presence of effective HAART; (4) drug screening of potential agents which traverse the blood-brain barrier and eliminate latent or other sources of residual virus in the CNS; and (5) design of therapeutic strategies aimed at eradication of HIV-1 from the CNS. Applications ranging from basic to translational research in domestic and international settings are of interest. Multidisciplinary research teams are encouraged but not required.

The National Institute of Mental Health (NIMH) and the National Institute of Neurological Disorders and Stroke (NINDS) invite novel research grant applications to address the problem of HIV-1 persistence focused solely on the central nervous system (CNS) of HIV-infected persons treated with Highly Active Anti-Retroviral Therapy (HAART). This Funding Opportunity Announcement (FOA) will support highly innovative research in five areas: (1) basic research to identify and characterize CNS-based cellular reservoirs of HIV-1 for individuals on HAART; (2) basic research to determine the mechanisms involved in the temporal establishment, maintenance, and resurgence of CNS-based HIV-1 reservoirs in relationship to the effects and timing of HAART, viral expression, and viral evolution within the brain; (3) development of physiologically relevant animal models and CNS-based cellular assays that recapitulate HIV-1 persistence and latency in the presence of effective HAART; (4) drug screening of potential agents which traverse the blood-brain barrier and eliminate latent or other sources of residual virus in the CNS; and (5) design of therapeutic strategies aimed at eradication of HIV-1 from the CNS. Applications ranging from basic to translational research in domestic and international settings are of interest. Multidisciplinary research teams are encouraged but not required.

The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted.Applications for administrative supplements are considered prior approval requests (as described in Section 8.1.2.11 of the NIH Grants Policy Statement) and will be routed directly to the Grants Management Officer of the parent award. Although requests for administrative supplements may be submitted through this FOA, there is no guarantee that funds are available from the awarding IC or for any specific grant. All applicants are encouraged to discuss potential requests with the awarding IC. Additionally, prior to submission, applicants must review the awarding IC's web site to ensure they meet the IC's requirements.A list of those web sites is available at http://grants.nih.gov/grants/guide/admin_supp/index.htm.

The National Institute of Neurological Disorders and Stroke (NINDS) invites applications for ancillary studies that will further our understanding of the unique clinical and biomarker signatures of premanifest or prodromal Huntington's disease (HD) through coordination with the NINDS-funded Neurobiological Predictors of Huntington's Disease (PREDICT-HD) study. The PREDICT-HD study is an international 32-site observational study of persons at-risk for HD, and includes clinical and biospecimen resources from 800 premanifest HD participants and 200 healthy control subjects. Extensive clinical data including UHDRS motor examination, cognitive and neuropsychiatric assessments, and structural MRI imaging have been collected over a ten-year time frame, with a subset of these data accessible through the dbGaP website http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs….

This Funding Opportunity Announcement (FOA) issued by the National Institutes of Health (NIH) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH awarding components identified in this FOA are encouraged to submit STTR grant applications in response to identified topics (see PHS 2012-2 SBIR/STTR Program Descriptions and Research Topics for NIH.)

The National Institute of Neurological Disorders and Stroke (NINDS) invites applications for a limited competition Funding Opportunity Announcement (FOA) utilizing a Cooperative Agreement (U01) to provide continuing support for Clinical and Data Coordinating Centers in the NIH Exploratory Trials in Parkinson's Disease network (NET-PD). The goal of this initiative is to support completion of NET-PD's current ongoing clinical trials.

This Funding Opportunity Announcement (FOA) issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA) and the Administration for Children and Families (ACF) invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH, CDC, FDA or ACF awarding components identified in this FOA are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2012-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, FDA and ACF

The National Institute of Neurological Disorders and Stroke (NINDS) invites applications for a limited competition Funding Opportunity Announcement (FOA) utilizing a Cooperative Agreement (U10) to provide continuing support for Clinical Sites in the NIH Exploratory Trials in Parkinson's Disease network (NET-PD). The goal of this initiative is to support completion of NET-PD's current ongoing clinical trials.

The purpose of this FOA is to encourage applications for the Leadership Group for a Clinical Research Network on Therapeutics for HIV/AIDS and HIV-associated Infections in Adults. The Leadership Group (LG) will have overall responsibility for developing, implementing and adapting the networks clinical research agenda to address NIAIDs HIV/AIDS scientific priorities described below (Part 2, Section I, #3). Applications for the LG must be comprised of three separate linked UM1 applications: a Leadership and Operations Center (LOC), a Laboratory Center (LC) and a Statistical and Data Management Center (SDMC).

This Funding Opportunity Announcement (FOA) issued by the National Institutes of Health, encourages applications that will develop novel technologies and/or tools to facilitate the study of genes and proteins at the synapse on a large scale. Being able to characterize the synaptome in the context of hundreds of genes/proteins would be a major advance for basic and translational research. The technologies/tools created would be expected to affect the fields of neurology, psychiatry, and neuroscience by enriching existing resources as well as those in development. The new tools should enable discovery science related to the synapse by providing for substantially greater sensitivity, selectivity, spatiotemporal resolution and markedly decreased costs compared to currently available technologies.